Agah Ramtin 4
4 · RenovoRx, Inc. · Filed Apr 7, 2026
Research Summary
AI-generated summary of this filing
RenovoRx (RNXT) CMO Agah Ramtin Receives Option Award
What Happened Agah Ramtin, Chief Medical Officer and Director of RenovoRx, was granted stock options covering 621,727 shares on April 3, 2026. The Form 4 reports this as an award/grant (derivative), with an acquisition price of $0 shown because these are option grants rather than a cash purchase of shares.
Key Details
- Transaction date: April 3, 2026; Form 4 filed April 7, 2026 (timely filing).
- Grant size: 621,727 stock options total — 319,073 incentive stock options (ISOs) and 302,654 non‑qualified stock options (NSOs).
- Vesting: monthly vesting at 1/48 per month, no cliff, vesting commencement effective January 1, 2026; fully vested January 1, 2030.
- Exercisability: options will only become exercisable when there is an effective registration statement covering the underlying shares.
- Expiration: options expire April 3, 2036.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Transaction type code: A (award/grant); this is a derivative grant, not a sale or open‑market purchase.
Context This filing documents an option grant (compensation), which is different from an immediate purchase or sale — no shares were transferred to open market by the insider at grant. Because exercisability depends on an effective registration statement, the options cannot currently be converted into tradable shares until that condition is met. This type of grant is common for executive compensation and does not by itself indicate buying or selling sentiment.
Insider Transaction Report
- Award
Stock Option
[F1]2026-04-03+621,727→ 621,727 totalExercise: $0.98→ Common Stock (621,727 underlying)
Footnotes (1)
- [F1]On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 621,727 shares of the Issuer's common stock (319,073 shares of which are underlying incentive stock options and 302,654 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036.